Sheets Smith Wealth Management Lowers Stock Position in CVS Health Corporation $CVS

Sheets Smith Wealth Management decreased its position in CVS Health Corporation (NYSE:CVS) by 76.0% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,214 shares of the pharmacy operator’s stock after selling 6,997 shares during the period. Sheets Smith Wealth Management’s holdings in CVS Health were worth $229,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the company. Elevation Wealth Partners LLC boosted its position in CVS Health by 41.8% during the second quarter. Elevation Wealth Partners LLC now owns 356 shares of the pharmacy operator’s stock worth $37,000 after purchasing an additional 105 shares in the last quarter. Apella Capital LLC increased its position in shares of CVS Health by 1.7% in the second quarter. Apella Capital LLC now owns 6,940 shares of the pharmacy operator’s stock valued at $724,000 after buying an additional 117 shares in the last quarter. CYBER HORNET ETFs LLC raised its stake in shares of CVS Health by 4.1% during the 3rd quarter. CYBER HORNET ETFs LLC now owns 3,442 shares of the pharmacy operator’s stock worth $259,000 after buying an additional 134 shares during the period. Northwestern Mutual Investment Management Company LLC lifted its position in shares of CVS Health by 0.3% during the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 40,560 shares of the pharmacy operator’s stock valued at $3,219,000 after buying an additional 136 shares in the last quarter. Finally, CoreCap Advisors LLC lifted its position in shares of CVS Health by 4.2% during the 2nd quarter. CoreCap Advisors LLC now owns 3,481 shares of the pharmacy operator’s stock valued at $360,000 after buying an additional 139 shares in the last quarter. 80.66% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

CVS has been the subject of a number of research analyst reports. Cantor Fitzgerald upped their price objective on shares of CVS Health from $100.00 to $110.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 7th. Mizuho lifted their target price on shares of CVS Health from $110.00 to $115.00 and gave the company an “outperform” rating in a research report on Monday, June 8th. Wall Street Zen raised shares of CVS Health from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 8th. UBS Group raised their price target on shares of CVS Health from $122.00 to $126.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Finally, Truist Financial lifted their price objective on CVS Health from $108.00 to $118.00 and gave the stock a “buy” rating in a report on Tuesday, July 14th. Twenty-two investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, CVS Health has an average rating of “Moderate Buy” and an average target price of $107.17.

More CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Pharmacy momentum supports the turnaround case. Rising prescription volumes, gains associated with Rite Aid and improving pharmacy profitability could provide support for CVS’s second-half outlook. This adds to the company’s recent earnings momentum, including revenue growth and an earnings beat in its latest reported quarter. How CVS’ Pharmacy and Consumer Wellness Is Positioned for H2 2026
• Positive Sentiment: Updated flu vaccines are now available nationwide. CVS Pharmacy and MinuteClinic are offering the 2026–2027 vaccines, while expanded testing and treatment services may increase seasonal customer traffic. A company survey found that more than 60% of consumers are likely to get a flu shot, though the earnings effect is likely to be seasonal and modest. CVS Pharmacy and MinuteClinic Now Offering Updated Flu Vaccines Nationwide
• Positive Sentiment: Value-focused coverage is reinforcing rebound expectations. Zacks characterizes CVS as a potential long-term value stock, while Trefis notes that the company’s historical drawdowns have often eventually recovered. These are sentiment and valuation arguments rather than new financial guidance, but they may attract investors seeking a healthcare turnaround at a relatively reasonable valuation. Why CVS Health Is a Top Value Stock for the Long-Term
• Neutral Sentiment: ACA insurer exits create both opportunity and uncertainty. Cigna, Molina and other carriers are leaving Obamacare exchanges in 2027. The disruption could create enrollment opportunities for Aetna, CVS’s insurance business, but also highlights regulatory, pricing and membership risks across the sector. All the Insurers Exiting ACA Obamacare Exchanges for 2027
• Negative Sentiment: Political pressure on vertically integrated healthcare companies remains a risk. Mark Cuban’s support for breaking up “big medicine” adds to scrutiny of insurers, pharmacy benefit managers and large healthcare platforms. No specific policy action against CVS was announced, but potential structural or regulatory changes could weigh on sentiment. Mark Cuban Backs Plan to Break Up Big Medicine

CVS Health Price Performance

CVS Health stock opened at $93.15 on Monday. The company has a fifty day simple moving average of $101.42 and a 200-day simple moving average of $89.55. The firm has a market capitalization of $119.14 billion, a price-to-earnings ratio of 24.64, a PEG ratio of 0.91 and a beta of 0.61. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.74. CVS Health Corporation has a 52-week low of $69.51 and a 52-week high of $110.68.

CVS Health (NYSE:CVS) last posted its quarterly earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $1.87 by $0.71. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. The firm had revenue of $106.10 billion for the quarter, compared to analyst estimates of $100.03 billion. During the same period in the previous year, the business posted $1.81 earnings per share. CVS Health’s quarterly revenue was up 7.3% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. On average, equities analysts anticipate that CVS Health Corporation will post 8.02 EPS for the current fiscal year.

CVS Health Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 23rd were given a $0.665 dividend. The ex-dividend date was Thursday, July 23rd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.9%. CVS Health’s dividend payout ratio is 70.37%.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over?the?counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in?store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk?in medical clinics and HealthHUB locations that offer expanded clinical services.